켄터키의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 15개가 켄터키 내 여러 지역에서 참여자를 모집하고 있습니다.
켄터키의 도시
공식 연구 텍스트(영어)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Norton Cancer Institute, Louisville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07258511A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT04634552Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Norton Healthcare Cancer Center, Louisville
피험자 모집 중관찰 연구
10세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT06323447A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Norton Cancer Institute St. Matthews, Louisville
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT07280013Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT03761108A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Research Site, Lexington
피험자 모집 중3상
18세 ~ 130세 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07735637Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Norton Women's and Children's Hospital, Louisville
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT06297226A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Louisville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07391657A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Norton Cancer Institute, Louisville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
- Norton Healthcare, Inc., Louisville
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT04879043Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- CommonSpirit Saint Joseph Hospital - Bardstown, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Radiation Oncology Resource Center, Lexington
- 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT04566328Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Louisville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Flaget Memorial Hospital, Bardstown
- Commonwealth Cancer Center-Corbin, Corbin
- Saint Joseph Hospital, Lexington
- 외 4개
피험자 모집 중3상
전 연령 · 모든 성별 · 2026. 6. 10. 업데이트됨 · NCT05561387CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Kentucky/ Markey Cancer Center, Lexington
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT05722418ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.